Guggenheim lowered the firm’s price target on Twist Bioscience (TWST) to $50 from $58 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience Stockholders Approve Key Amendments
- Cathie Wood’s ARK Investment bought 268K shares of Twist Bioscience today
- Twist Bioscience: Hold Rating Maintained Amidst Growth Concerns and Competitive Pressures
- Twist Bioscience price target raised to $62 from $54 at Scotiabank
- Twist Bioscience price target raised to $54 from $48 at Baird